When does Pharming report earnings and why does it matter for PHARM.AS stock?

Pharming reports on **12 Mar 2026**; investors watch RUCONEST revenue, Joenja uptake and guidance. The release can shift PHARM.AS stock sentiment quickly since revenue mix and clinical updates drive near-term valuation.

What is Meyka AI's 12-month forecast for PHARM.AS stock?

Meyka AI's 12-month forecast for PHARM.AS stock is **EUR 2.04**, implying about **53.13%** upside versus the current **EUR 1.33**. Forecasts are model-based and not guarantees.

Are Pharming’s valuation metrics attractive ahead of earnings?

Valuation is mixed: Price/Sales **2.97** and Price/Book **3.90** show growth pricing, while EPS is negative (**-0.01**), so PE ratios are not meaningful. Cash flow metrics and current ratio support liquidity.

How should traders manage risk around the PHARM.AS earnings date?

Manage risk with smaller position sizes, staggered entries, or protective collars. Consider stop ranges near **EUR 1.10–1.20** and wait for volume-backed moves above **EUR 1.47** for bullish trades.

EU Stocks

Earnings 12 Mar: PHARM.AS Pharming (EURONEXT) pre-market 07 Mar 2026 what to watch

ByDanny Kontos March 7, 2026

PHARM.AS stock trades at EUR 1.33 in pre-market trade on 07 Mar 2026 as investors brace for an earnings release on 12 Mar 2026. Volume is elevated at 10,536,744 shares and the price is down -1.55% on the day. Expect the report to focus on RUCONEST sales, Joenja commercialization progress, and guidance for 2026 in EURONEXT-listed Pharming Group N.V. (Europe). We flag valuation, cash flow and clinical readouts as the main drivers for near-term moves.